On this page
Bronchogen Quick Reference (20 mg Vial)
- Vial contents
- 20 mg Bronchogen
- Final volume
- 3 mL
- Concentration
- 6.67 mg/mL
- One U-100 unit
- 66.67 mcg in 0.01 mL
Bronchogen Dosage Chart
Dosing & Reconstitution Guide
Community-Reported Use Calculations (3.0 mL = 6.667 mg/mL)
Community-Reported Use Calculations (3.0 mL = 6.667 mg/mL)
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 10 days | 1 mg | 15 units (0.15 mL) |
| 20 days | 1 mg | 15 units (0.15 mL) |
| 10 days | 2 mg | 30 units (0.30 mL) |
| 20 days | 2 mg | 30 units (0.30 mL) |
Frequency: Once daily in the reviewed community descriptions. Each row is an independent calculation, not a titration schedule.
Research reference only: The 1 to 2 mg once-daily, 10 to 20 day patterns are nonclinical community descriptions. No academic Bronchogen study establishes these schedule numbers, a human route, or a validated recommendation.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with compound, concentration, and preparation date. Store it according to verified product-specific instructions.
Supplies Needed
Choose the supply row that matches the single calculation period being reviewed. Do not add the rows together.
- Peptide Vials (Bronchogen, 20 mg each):
- 10 days at 1 mg/day: 1 vial
- 20 days at 1 mg/day: 1 vial
- 10 days at 2 mg/day: 1 vial
- 20 days at 2 mg/day: 2 vials
- Insulin Syringes (U-100):
- 10-day calculations: 10 syringes
- 20-day calculations: 20 syringes
- Bacteriostatic Water (10 mL bottle):
- One-vial calculations: 3.0 mL
- Two-vial calculation: 6.0 mL
- Alcohol Swabs:
- 10-day calculations: 20 swabs
- 20-day calculations: 40 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.
Bronchogen Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water for a calculated concentration of 6.667 mg/mL.
- Vial contents: 20 mg Bronchogen.
- U-100 conversion: At 6.667 mg/mL, 1 unit = 0.01 mL = 66.667 mcg.
- Storage: Follow the exact product label and laboratory stability instructions. Do not infer a universal use-by period from vial strength alone.
Published Bronchogen research is limited to cell and animal models.[1][2][3][4] The literature also contains an identity discrepancy: one abstract uses ADEL, while another identifies Bronchogen as AEDL.[1][4]
What the Bronchogen Research Does and Does Not Establish
Bronchogen is described as an ultrashort tetrapeptide in laboratory literature. Human embryonic bronchial epithelial cells, rat nitrogen-dioxide models, and molecular studies are not human clinical trials.[1][2][3][4] Reviews discuss possible gene-regulatory and transport mechanisms for ultrashort peptides but do not establish Bronchogen pharmacokinetics or dosing in people.[5][6]
No published human dosing trial establishes a validated Bronchogen amount, route, frequency, duration, safety profile, or treatment effect. The dosage chart is therefore labeled as community-reported use, and the academic references support only identity, mechanisms, model findings, and evidence limits.
The sequence discrepancy between ADEL and AEDL should be resolved against product-specific analytical documentation before interpreting the vial.[1][4]
20 mg Vial Calculation Notes
- 20 mg divided by 3.0 mL equals 6.667 mg/mL.
- One U-100 unit equals 0.01 mL or 66.667 mcg.
- 1 mg equals 15 units (0.15 mL).
- 2 mg equals 30 units (0.30 mL).
Evidence Limits and Safety
References
- 1Khavinson et al., 2014, PMID 25015171 – Primary human embryonic bronchial epithelial cell-culture study; the abstract identifies the tetrapeptide as ADEL. This is not a human clinical dosing study.
- 2Khavinson et al., 2015, PMID 26468022 – Rat nitrogen-dioxide model examining Bronchogen and bronchial epithelium over one month.
- 3Linkova et al., 2018, PMID 30199201 – Rat chronic obstructive pulmonary disease model examining peptide-related molecular markers.
- 4Fedoreyeva et al., 2011, PMID 22117547 – Cell and biochemical study identifying Bronchogen as AEDL and examining nuclear localization and DNA interactions.
- 5Khavinson et al., 2021, PMID 34834147 – Systematic review of short-peptide regulation of gene expression and the supporting model evidence.
- 6Khavinson et al., 2022, PMID 35887081 – Review of proposed transport mechanisms for biologically active ultrashort peptides.
- 7U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance describing evidence expectations for peptide drug development.
- 8European Medicines Agency, Development and Manufacture of Synthetic Peptides – Scientific guideline addressing identity, manufacture, quality, and impurity control for synthetic peptides.